continue increasing competition by introducing oral GLP-1, dual incretin and novel metabolic drugs
While numerous proof-of-concept candidate molecules have been disclosed ( and Zepbound ) ( ex vivo finding, the GIPR monoagonist LY3537021 reduced body weight by ~4.1% over 8 weeks in patients with T2D (n = 18) ( 2.2 GIPR agonism serves to reduce GLP-1R mediated GI AEs in the clinic Treatment with GLP-1R agonists can drive nausea, diarrhea, vomiting, and constipation, which often results in discontinuation of treatment (6-10% of patients) or reduction in dose (~15% of patients) ( It has been hypothesized that the deleterious, nauseating effects of GLP-1R agonists and the beneficial, food-intake reducing effects are inextricably linked
Side effects, cost, accessibility, long-term sustainability, and what happens after you stop, all of these factors matter just as much as the number on the scale
For mild deficiencies, you may need 2-3 injections over several weeks to notice the impact
Understanding how to prevent skin thinning during a GLP-1 regimen requires recognising that these changes typically result from rapid fat loss rather than direct drug effects on dermal tissue
Genetic factors can influence appetite, feelings of fullness, and how the body uses energycore processes involved in weight regulation
